Loading...
In the Heart and Estrogen/progestin Replacement Study (HERS), researchers found no cardiovascular benefit from combined estrogen-progesterone replacement therapy in women with known coronary heart disease (CHD; Journal Watch Jul 26 2002). Hard on the heels of the HERS findings, the data- and safety-monitoring committee of the Women's Health Initiative (WHI) halted, after a mean follow-up of 5.2 years, a planned 8.5-year, randomized, controlled trial of the risks and benefits of combined hormone replacement therapy in healthy women. In this trial, 16,608 women (mean age, 63) with intact uteri were randomized to receive either conjugated equine estrogen (0.625 mg/day) combined with medroxyprogesterone (2.5 mg/day), or placebo.
Compared with pl…